J&J invests $500m into global HIV and TB treatment

Johnson & Johnson (J&J) has committed $500 million to research and development programmes over the next four years in a bid to eliminate HIV and tuberculosis (TB) across the world by 2030.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Global Drug Facility adds new TB drug to its catalogue

31 October 2019 The Global Drug Facility, which provides tuberculosis treatments to those in need in 150 countries, has listed a new drug to its product catalogue.

Big Pharma

Federal Circuit rules against J&J in Zytiga dispute

16 May 2019 The US Court of Appeals for the Federal Circuit delivered a blow to Johnson & Johnson on Tuesday, May 14, by confirming the invalidation of a patent covering blockbuster prostate cancer drug Zytiga.

More features

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

J&J invests $500m into global HIV and TB treatment

More on this story

Editor's picks

Editor's picks

More features